Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Atara Biotherap (ATRA)

Atara Biotherap (ATRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,086
  • Shares Outstanding, K 4,915
  • Annual Sales, $ 8,570 K
  • Annual Income, $ -276,130 K
  • EBIT $ -179 M
  • EBITDA $ -173 M
  • 60-Month Beta 0.50
  • Price/Sales 5.09
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 63.70%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,337.57% on 01/11/24
  • IV Low 0.00% on 10/24/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 17
  • Open Int (30-Day) 17

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -3.77
  • Number of Estimates 2
  • High Estimate -2.87
  • Low Estimate -4.67
  • Prior Year -16.50
  • Growth Rate Est. (year over year) +77.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.20 +23.75%
on 10/03/24
10.05 -11.34%
on 10/18/24
+0.78 (+9.59%)
since 09/30/24
3-Month
6.50 +37.08%
on 08/16/24
10.69 -16.65%
on 09/05/24
-0.72 (-7.48%)
since 07/30/24
52-Week
4.96 +79.46%
on 11/13/23
39.50 -77.44%
on 02/02/24
-23.34 (-72.37%)
since 10/30/23

Most Recent Stories

More News
Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Biotherapeutics: Q2 Earnings Snapshot

ATRA : 8.91 (-6.99%)
1 Penny Stock Where You Can Spend Less And Earn More

This tiny stock could soar more than 400%, according to Wall Street.

ATRA : 8.91 (-6.99%)
$SPX : 5,705.45 (-1.86%)
Atara Biotherapeutics: Q1 Earnings Snapshot

Atara Biotherapeutics: Q1 Earnings Snapshot

ATRA : 8.91 (-6.99%)
Atara Biotherapeutics: Q4 Earnings Snapshot

Atara Biotherapeutics: Q4 Earnings Snapshot

ATRA : 8.91 (-6.99%)
Atara Biotherapeutics: Q3 Earnings Snapshot

Atara Biotherapeutics: Q3 Earnings Snapshot

ATRA : 8.91 (-6.99%)
Atara Biotherapeutics: Q2 Earnings Snapshot

Atara Biotherapeutics: Q2 Earnings Snapshot

ATRA : 8.91 (-6.99%)
Atara Biotherapeutics: Q1 Earnings Snapshot

Atara Biotherapeutics: Q1 Earnings Snapshot

ATRA : 8.91 (-6.99%)
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 8.91 (-6.99%)
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 8.91 (-6.99%)
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

ATRA : 8.91 (-6.99%)

Business Summary

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta...

See More

Key Turning Points

3rd Resistance Point 10.24
2nd Resistance Point 9.97
1st Resistance Point 9.44
Last Price 8.91
1st Support Level 8.64
2nd Support Level 8.37
3rd Support Level 7.84

See More

52-Week High 39.50
Fibonacci 61.8% 26.31
Fibonacci 50% 22.23
Fibonacci 38.2% 18.16
Last Price 8.91
52-Week Low 4.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar